Related Experiment Video

Updated: Jul 13, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells

Daniel Nowak1, Simone Boehrer, Simone Hochmuth

  • 1Department of Internal Medicine II, Hematology and Oncology, University Hospital, Theodor-Stern-Kai Germany.

Anti-Cancer Drugs
|August 21, 2007
PubMed

Insights

Novel dual selective Src/Abl kinase inhibitors (SrcK-I) induce apoptosis and cell cycle arrest in specific lymphoma cell lines. These Src kinase inhibitors show promise for targeting lymphoma cells by downregulating key survival proteins.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Src kinases regulate critical cellular processes including proliferation, adhesion, and apoptosis.
  • Dysregulation of Src kinases is implicated in various cancers, including lymphoma.
  • Targeting Src kinases presents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of three novel dual selective Src/Abl kinase inhibitors (SrcK-I) in lymphoma cell lines.
  • To investigate the mechanisms by which SrcK-I affect lymphoma cell viability and apoptosis.
  • To identify potential biomarkers for sensitivity or resistance to SrcK-I therapy.

Main Methods:

  • Treatment of multiple lymphoma cell lines (DOHH-2, WSU-NHL, Raji, Karpas-299, HUT78, Jurkat) with SrcK-I (AZM559756, AZD0530, AZD0424).
  • Assessment of apoptosis induction and cell cycle arrest.
  • Analysis of protein phosphorylation (Lyn, Lck, Akt) and expression levels (c-abl, survivin, Bcl-XL, c-FLIP, c-Myc).

Main Results:

  • SrcK-I induced apoptosis and cell cycle arrest in DOHH-2 and WSU-NHL cell lines, but not others.
  • Phosphorylation of Lyn and Lck kinases was significantly affected by SrcK-I treatment.
  • SrcK-I treatment led to downregulation of survivin, Bcl-XL, c-FLIP, c-abl, and decreased Akt phosphorylation.
  • Lower basal c-Myc expression correlated with sensitivity to SrcK-I.

Conclusions:

  • Novel dual selective Src/Abl kinase inhibitors demonstrate potent anti-lymphoma activity in specific cell lines.
  • The observed effects are mediated through modulation of apoptosis pathways and key signaling proteins.
  • c-Myc expression may serve as a predictive marker for response to SrcK-I therapy in lymphoma.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...